PP
RVNC

PDT Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

PDT Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-197,049
Closed -$506K – 849
2024
Q2 		$506K Buy
+197,049
New +$673K 0.05% 462
2022
Q4 		– Sell
-45,800
Closed -$1.24M – 935
2022
Q3 		$1.24M Sell
45,800
-64,890
-59% -$1.32M 0.19% 161
2022
Q2 		$1.53M Buy
+110,690
New +$1.7M 0.13% 243
2015
Q3 		– Sell
-18,718
Closed -$599K – 1623
2015
Q2 		$599K Buy
+18,718
New +$481K 0.02% 913
2014
Q4 		– Sell
-42,070
Closed -$813K – 1149
2014
Q3 		$813K Buy
42,070
+6,266
+18% +$163K 0.02% 771
2014
Q2 		$1.22M Buy
+35,804
New +$1.12M 0.03% 631

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

PDT Partners's RVNC Position: Q3 2024 in Review

PDT Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 197,049 shares — an estimated $506K sold.

PDT Partners first reported a position in RVNC in Q2 2014 and held it in 6 quarters. The position peaked at $1.53M in Q2 2022. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • PDT Partners reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • PDT Partners sold 197,049 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $506K.
  • PDT Partners first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 6 quarters.
  • PDT Partners's Revance Therapeutics, Inc. position peaked at $1.53M in Q2 2022.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on PDT Partners's 13F filing for Q3 2024, filed 14 Nov 2024.